Avantor (AVTR) AI Stock Analysis

• Market Cap: $7.45B
• Dividend Yield: N/A
• Average Volume (3M): 10.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.70
• Revenue Growth: -3.59%
• EPS Growth: -126.16%
• Country: US
• Employees: 13,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.22
• Shares Outstanding: 681,814,900
• 10 Day Avg. Volume: 13,076,590
• 30 Day Avg. Volume: 10,507,461
• PEG Ratio: 0.17
• Price to Book (P/B): 2.41
• Price to Sales (P/S): 2.11
• P/FCF Ratio: 20.71
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 1.68
• Enterprise Value/Gross Profit: 5.07
• Enterprise Value/Ebitda: 17.14
• 1Y Price Target: $11.71
• Price Target Upside: 7.23% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $12.50 ▲(14.47% Upside)

Avantor's overall stock score reflects significant challenges in financial performance and valuation, with declining revenue and profitability being major concerns. Technical analysis indicates weak momentum, and while recent corporate events and strategic initiatives offer some hope for improvement, the current operational and market pressures weigh heavily on the stock's outlook.

Positive Factors

Diversified, mission-critical customer base

Avantor supplies essential lab consumables, chemicals and services to pharma, biotech and advanced tech with long-term contracts. This creates sticky demand and revenue resilience, supporting durable topline stability across research and production cycles.

Clear cost-transformation and turnaround plan

Management’s Avantor Revival program targets substantial operational savings and simplification through 2027. If executed, $400m run-rate savings should materially improve margins, cash generation and competitiveness over the medium term, addressing structural inefficiencies.

Improved leverage and liquidity after refinancing

Refinancing extended maturities and increased liquidity while lowering financing costs, and debt-to-equity is a moderate 0.69 TTM. Greater financial flexibility reduces refinancing risk and supports execution of operational improvements without immediate balance-sheet pressure.

Negative Factors

Persistent revenue decline

Quarterly organic revenue declines and reduced full-year guidance (organic -3.5% to -2.5%) indicate ongoing demand or market-share pressures. Sustained revenue contraction limits scale benefits and hinders margin recovery absent durable improvement in commercial execution.

Weak profitability and returns

Negative net margin and a negative ROE highlight structural profitability shortfalls. Persistent low or negative returns constrain reinvestment, debt reduction and shareholder returns, increasing reliance on cost cuts and operational fixes to restore sustainable earnings.

Operational disruptions and goodwill impairment

A large goodwill impairment and noted raw-material constraints, equipment downtime and bioprocessing backlog signal execution weaknesses. These structural operational issues can depress margins, delay revenue recognition and raise capital needs until reliability and capacity are restored.

Avantor Business Overview & Revenue Model

Company Description

Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.

How the Company Makes Money

Avantor generates revenue primarily through the sale of its products and services to customers in the pharmaceutical, biotechnology, and advanced materials industries. Key revenue streams include the sale of essential laboratory supplies, specialty chemicals, and equipment, as well as customized services tailored to meet the specific needs of clients. The company benefits from long-term contracts and relationships with major pharmaceutical and biotechnology firms, which provide a stable revenue base. Additionally, Avantor's focus on innovation and product development, along with strategic partnerships and collaborations with research institutions and industry leaders, further enhances its revenue potential. The company's global footprint and operational efficiency also contribute to its profitability by allowing it to scale operations and reduce costs effectively.

Avantor Financial Statement Overview

Summary

Avantor faces challenges with declining revenue and profitability, as reflected in the negative net profit margin and revenue growth rate. The balance sheet shows improved leverage but struggles with generating shareholder returns. Cash flow metrics indicate some resilience in cash conversion, though growth is declining. The company needs to address operational inefficiencies and enhance profitability to improve its financial health.

Income Statement

Avantor's income statement shows a declining trend in revenue with a negative revenue growth rate of -1.36% TTM. The gross profit margin remains relatively stable at 33.13%, but the net profit margin has turned negative at -1.25% TTM, indicating profitability challenges. The EBIT and EBITDA margins have also decreased significantly compared to previous years, reflecting operational inefficiencies.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.69 TTM, which is an improvement from previous years, indicating better leverage management. However, the return on equity is negative at -1.38% TTM, highlighting issues in generating returns for shareholders. The equity ratio stands at 47.70%, suggesting a balanced capital structure.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by -5.81% TTM, indicating potential cash generation issues. The operating cash flow to net income ratio is 0.42, suggesting that operating cash flow is not fully covering net income. The free cash flow to net income ratio is relatively strong at 0.81, indicating decent cash conversion despite profitability challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.58B	6.78B	6.97B	7.51B	7.39B	6.39B
Gross Profit	2.18B	2.28B	2.36B	2.60B	2.50B	2.08B
EBITDA	644.60M	1.48B	1.10B	1.52B	1.35B	765.30M
Net Income	-82.20M	711.50M	321.10M	686.50M	572.60M	116.60M
Balance Sheet
Total Assets	11.68B	12.11B	12.97B	13.46B	13.90B	9.91B
Cash, Cash Equivalents and Short-Term Investments	251.90M	261.90M	262.90M	372.90M	301.70M	286.60M
Total Debt	3.86B	4.23B	5.54B	6.29B	7.02B	4.89B
Total Liabilities	6.11B	6.16B	7.72B	8.61B	9.70B	7.23B
Stockholders Equity	5.57B	5.96B	5.25B	4.86B	4.20B	2.67B
Cash Flow
Free Cash Flow	523.60M	692.00M	723.60M	710.20M	842.50M	868.20M
Operating Cash Flow	644.40M	840.80M	870.00M	843.60M	953.60M	929.80M
Investing Cash Flow	467.70M	438.90M	-143.70M	-109.60M	-4.12B	-59.10M
Financing Cash Flow	-1.17B	-1.28B	-843.70M	-648.70M	3.22B	-782.90M

Avantor Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Negative. The current price of 10.92 is below the 20-day moving average (MA) of 11.90, below the 50-day MA of 11.54, and below the 200-day MA of 12.72, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 36.72 is Neutral, neither overbought nor oversold. The STOCH value of 7.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTR.

Avantor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EMN	72 Outperform	$7.91B	16.91	―	5.33%	-3.33%	-19.59%
SQM	63 Neutral	$21.97B	42.14	9.87%	―	-10.07%	―
ALB	58 Neutral	$20.08B	-106.86	-0.21%	1.10%	-23.92%	90.47%
KWR	58 Neutral	$2.67B	-301.81	-0.64%	1.37%	0.08%	-107.33%
WLK	56 Neutral	$10.17B	-10.69	-9.48%	2.88%	-5.32%	-1108.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AVTR	48 Neutral	$7.45B	-89.66	-1.48%	―	-3.59%	-126.16%

Avantor Corporate Events

Avantor appoints Simon Dingemans to board of directors

On December 17, 2025, Avantor, Inc.’s board of directors elected veteran finance and investment executive Simon Dingemans as a director, effective January 2, 2026, to fill the vacancy created by Jonathan Peacock’s previously announced resignation effective December 31, 2025. Dingemans, a former Chief Financial Officer of GSK and senior leader at The Carlyle Group and Goldman Sachs, has been deemed independent under New York Stock Exchange and U.S. securities law standards and will receive Avantor’s standard non-employee director compensation package, including a prorated cash retainer and restricted stock units scheduled to vest in May 2026, reflecting the company’s continued effort to strengthen its board with experienced global corporate and financial leadership.

The most recent analyst rating on (AVTR) stock is a Sell with a $9.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Appoints Sanjeev Mehra to Board of Directors

On December 4, 2025, Avantor, Inc. announced the election of Sanjeev Mehra to its Board of Directors, with his term set to expire at the company’s 2026 Annual Meeting of Stockholders. Mr. Mehra brings extensive experience from his roles at Periphas Capital and Goldman Sachs, enhancing Avantor’s strategic direction and governance. His appointment is expected to strengthen Avantor’s board with his expertise in private equity and investment management, potentially impacting the company’s market positioning and stakeholder interests.

The most recent analyst rating on (AVTR) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.

Avantor Appoints Mary Blenn as COO

On November 10, 2025, Avantor announced the appointment of Mary Blenn as Executive Vice President and Chief Operating Officer. With over three decades of experience in global operations, manufacturing, and supply chain leadership, Ms. Blenn will lead Avantor’s manufacturing and supply chain operations, aligning them with the company’s growth strategy. Her expertise in transforming complex operations and leading large-scale organizations through periods of rapid growth is expected to enhance Avantor’s operational excellence and customer service.

The most recent analyst rating on (AVTR) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Avantor stock, see the AVTR Stock Forecast page.